Navigating Diabetes Mellitus: Advancing Forward

Journal: South East Asia Journal of Medical Sciences

Article type: Research Article

Published: 2024-01-15

Volume: 8; Issue: 1; Pages: 23-31

ISSN: 2522-7165

Article URL: https://journals.littlebaypublishers.com/article/article-1783008743579-248438681

PDF: https://journals.littlebaypublishers.com/article/article-1783008743579-248438681.pdf

JATS XML: https://journals.littlebaypublishers.com/article/article-1783008743579-248438681.xml

Authors

  1. Mohd Altaf Dar
    Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab
  2. Zulfkar Qadrie
    Senior Resident, Department of Pharmacology, Government Medical College Baramulla

Abstract

Diabetes Mellitus (DM) is a group of metabolic diseases characterized by an elevated blood glucose level – resulting from defects in insulin secretion, in insulin action or both. Diabetes Mellitus is not a pathogenic entity but a group of etiologically different metabolic defects that share the phenotype of hyperglycemia. Several distinct types of DM exist and are caused by complex interaction of genetic factors and life style choices. The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system. Intensive diabetes management has set the goal of improvement of glycemic control, which reduces complications associated with the diseases. A strict control of blood glucose levels (Ideally HbA1c< 7% mean plasma glucose level, < 150 mg/dl) delays the onset and progression of diabetic neuropathy, nephropathy, retinopathy, and reduction in cardiovascular risk. Sulfonylureas (Glebenclemide, Gliclazide, Glemiperide, and tolbutamide), Biguandies (Metformin, Phenformin) are effectively used in controlling elevated blood glucose levels in oral antidiabetic therapy. . Sitagliptin is a once-daily, orally active, potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor approved in many countries for the treatment of patients with type- 2 diabetes. Sitagliptin was the first DPP-4 inhibitor that was approved for the management of type 2 diabetes in 2007. Sitagliptin is being used as monotherapy (100 or 200 mg OD) or as an add-on to ongoing oral antidiabetic agents (OAD) in patients with type 2 diabetes with significant reduction in glycaemic levels within a few weeks. In this review, we will briefly study the different therapeutic options available for the management of Diabetes Mellitus. Keywords : Diabetes mellitus, Insulin, Sulfonylureas, Biguanides, Sitagliptin.

Keywords

Diabetes mellitus, Insulin, Sulfonylureas, Biguanides, Sitagliptin

Full Text

HTML full text is not available. Refer to the PDF galley.